We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$522M
AUM Growth
-$60.9M
Cap. Flow
+$27.1M
Cap. Flow %
5.19%
Top 10 Hldgs %
45.15%
Holding
120
New
43
Increased
21
Reduced
16
Closed
38

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$22.2M
2
BHVN icon
Biohaven
BHVN
+$17.4M
3
MBX
MBX Biosciences
MBX
+$14.3M
4
CGON icon
CG Oncology
CGON
+$11.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$10.9M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$28.9M
2
ACLX
Arcellx
ACLX
+$21.7M
3
TWST icon
Twist Bioscience
TWST
+$21.3M
4
TERN
Terns Pharmaceuticals
TERN
+$17.6M
5
ROIV icon
Roivant Sciences
ROIV
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Financials 0.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
76
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$85.5K 0.02%
+50,000
New +$34M
QQQ icon
77
CALL
Invesco QQQ Trust
QQQ
$466B
$74.2K 0.01%
+40,000
New +$24.3M
VTGN icon
78
VistaGen Therapeutics
VTGN
$9.4M
$58.2K 0.01%
616,749
– –
BSX icon
79
CALL
Boston Scientific
BSX
$65.4B
$12.5K ﹤0.01%
+250,000
New +$20M
TERN
80
CALL
DELISTED
Terns Pharmaceuticals
TERN
$7.5K ﹤0.01%
+100,000
New +$4.11M
OLMA icon
81
CALL
Olema Pharmaceuticals
OLMA
$1B
$3.75K ﹤0.01%
+25,000
New +$557K
EW icon
82
CALL
Edwards Lifesciences
EW
$49.4B
$1K ﹤0.01%
+10,000
New +$824K
ABBV icon
83
AbbVie
ABBV
$450B
– –
-9,325
Closed -$2.13M
ABUS icon
84
Arbutus Biopharma
ABUS
$901M
– –
-986,751
Closed -$4.75M
ACLX
85
DELISTED
Arcellx
ACLX
– –
-332,860
Closed -$21.7M
ADCT icon
86
ADC Therapeutics
ADCT
$172M
– –
-502,570
Closed -$1.77M
ADPT icon
87
Adaptive Biotechnologies
ADPT
$3.67B
– –
-606,825
Closed -$9.85M
APGE icon
88
Apogee Therapeutics
APGE
$10.1B
– –
-80,574
Closed -$6.08M
ASND icon
89
Ascendis Pharma A/S
ASND
$17.1B
– –
-14,842
Closed -$3.16M
BLTE
90
Belite Bio
BLTE
$6.02B
– –
-9,163
Closed -$1.47M
CLPT icon
91
ClearPoint Neuro
CLPT
$454M
– –
-481,858
Closed -$6.59M
CNTA
92
CALL
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-75,000
Closed -$26.3K
CNTA
93
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-1,154,114
Closed -$28.9M
CTMX icon
94
CytomX Therapeutics
CTMX
$788M
– –
-1,036,311
Closed -$4.41M
DRUG
95
Bright Minds Biosciences
DRUG
$747M
– –
-97,340
Closed -$7.6M
GLUE icon
96
Monte Rosa Therapeutics
GLUE
$2.07B
– –
-61,577
Closed -$966K
IDYA icon
97
IDEAYA Biosciences
IDYA
$3.47B
– –
-161,659
Closed -$5.59M
IMTX icon
98
Immatics
IMTX
$1.31B
– –
-610,308
Closed -$6.41M
INCY icon
99
Incyte
INCY
$23.4B
– –
-61,435
Closed -$6.07M
IVA
100
Inventiva
IVA
$1.09B
– –
-467,242
Closed -$2.17M
1 2 3
4
5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Stempoint Capital held 120 positions worth $522M, down 10% from $583M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Stempoint Capital deployed $27.1M of net new capital in Q1 2026, opening 43 new positions and adding to 21 existing holdings. Its largest new stake was Biohaven: 1,594,491 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $21.3M trimmed.

  • Stempoint Capital's largest Q1 2026 buy was Biohaven: 1,594,491 shares worth $13.5M.
  • Stempoint Capital added most to Revolution Medicines in Q1 2026, an estimated $22.2M increase.
  • Stempoint Capital's biggest Q1 2026 reduction was Twist Bioscience, cutting an estimated $21.3M.
  • Stempoint Capital fully exited Centessa Pharmaceuticals in Q1 2026, selling an estimated $28.9M.
  • Stempoint Capital's ten largest holdings make up 45% of its $522M portfolio in Q1 2026.
  • Stempoint Capital opened 43 new positions and closed 38 in Q1 2026.
  • Stempoint Capital's portfolio value fell 10% quarter-over-quarter to $522M.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.